Ovarian cancer is the sixth most common malignancy among women in developed countries and the fifth leading cause of cancer-related death, representing a complex disease associated with poor survival rates.24 The combination chemotherapy of Paclitaxel (PTX) and Carboplatin (CARB) is considered the first-line treatment regimen for ovarian cancer.25 Both agents play distinct roles in inhibiting the growth of ovarian cancer through different mechanisms,26 and they are known to exert a synergistic anti-tumor effect by activating separate apoptotic signaling pathways, thereby potentially reducing drug resistance.25 The gonadotoxic effects of platinum-based chemotherapeutic agents have been demonstrated in numerous studies, both histopathologically and in terms of follicular development.27-29 In the present study, CARB administration led to significant histopathological damage in ovarian tissue, including follicular degeneration, prominent stromal edema, congestion, hemorrhage, inflammation, and fibrosis, particularly in the medullary region
The medication's contraindication applies to pregnancy itself (the pregnant person taking the medication), not to the reproductive contributions of a partner
Drugs Under Market Approval Application Currently, there are 8 single-target GLP1R drugs in the market approval application stage
Conclusion and future perspectives As shown in the Figure 4 , cysteine has different fates including the synthesis of cysteine-derived molecule, sulfur/carbon metabolic reprogramming, and venue for post-translational protein modification of various proteins or discovery of drug inhibitors
C.LuqueG
An experienced doctor will determine dosing to ensure safety and effectiveness and monitor progress to assess whether any adjustments need to be made
